Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (23) 23
humans (21) 21
cardiac & cardiovascular systems (15) 15
female (15) 15
abridged index medicus (13) 13
male (13) 13
middle aged (12) 12
aged (11) 11
myocardial infarction (8) 8
risk factors (8) 8
care and treatment (7) 7
prevention (7) 7
stroke (7) 7
ticagrelor (7) 7
treatment outcome (7) 7
cardiovascular disease (6) 6
dosage and administration (6) 6
double-blind method (6) 6
health aspects (6) 6
mortality (6) 6
obesity (6) 6
peripheral vascular disease (6) 6
adenosine - analogs & derivatives (5) 5
analysis (5) 5
clopidogrel (5) 5
exercise (5) 5
follow-up studies (5) 5
heart attacks (5) 5
heart failure (5) 5
hemorrhage - chemically induced (5) 5
risk (5) 5
secondary prevention (5) 5
usage (5) 5
acute coronary syndromes (4) 4
adenosine - administration & dosage (4) 4
adenosine - adverse effects (4) 4
aspirin (4) 4
atrial fibrillation (4) 4
body mass index (4) 4
cardiovascular diseases (4) 4
child (4) 4
clinical trials (4) 4
coronary artery disease (4) 4
diabetes (4) 4
drug therapy (4) 4
heart attack (4) 4
internal medicine (4) 4
management (4) 4
myocardial infarction - drug therapy (4) 4
overweight (4) 4
physical activity (4) 4
prevalence (4) 4
purinergic p2y receptor antagonists - administration & dosage (4) 4
research (4) 4
united-states (4) 4
warfarin (4) 4
adolescents (3) 3
anticoagulants (3) 3
behavior (3) 3
beverages (3) 3
confidence intervals (3) 3
diet (3) 3
disease (3) 3
dose-response relationship, drug (3) 3
drug administration schedule (3) 3
guidelines (3) 3
health behavior (3) 3
health promotion (3) 3
heart diseases (3) 3
language arts (3) 3
medicine, general & internal (3) 3
myocardial-infarction (3) 3
physical-activity (3) 3
purinergic p2y receptor antagonists - adverse effects (3) 3
pyridines - adverse effects (3) 3
safety (3) 3
statin therapy (3) 3
stroke - prevention & control (3) 3
therapy (3) 3
time factors (3) 3
adenosine - pharmacokinetics (2) 2
adenosine-diphosphate (2) 2
adult (2) 2
adults (2) 2
aged, 80 and over (2) 2
anticoagulation (2) 2
antiplatelet therapy (2) 2
arteriosclerosis (2) 2
artery-disease (2) 2
association (2) 2
atrial fibrillation - complications (2) 2
biomarker (2) 2
blood platelets - drug effects (2) 2
body weight (2) 2
body-mass index (2) 2
cardiac and cardiovascular systems (2) 2
cardiology (2) 2
cardiorespiratory fitness (2) 2
cardiovascular (2) 2
cardiovascular diseases - complications (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
by Sabatine, Marc S and Giugliano, Robert P and Keech, Anthony C and Honarpour, Narimon and Wiviott, Stephen D and Murphy, Sabina A and Kuder, Julia F and Wang, Huei and Liu, Thomas and Wasserman, Scott M and Sever, Peter S and Pedersen, Terje R and FOURIER Steering Comm Investigator and FOURIER Steering Committee and Investigators
The New England Journal of Medicine, ISSN 0028-4793, 05/2017, Volume 376, Issue 18, pp. 1713 - 1722
In this trial, 27,564 patients with cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter or higher on statin therapy were assigned to... 
MODERATE | MEDICINE, GENERAL & INTERNAL | STATIN THERAPY | LDL-C | REDUCING LIPIDS | PCSK9 INHIBITION | RISK | PLACEBO-CONTROLLED TRIAL | HYPERCHOLESTEROLEMIA | CORONARY-HEART-DISEASE | EZETIMIBE | Atherosclerosis - drug therapy | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Incidence | Cardiovascular Diseases - complications | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Least-Squares Analysis | Cholesterol, LDL - blood | Female | Hypercholesterolemia - complications | Aged | Drug Therapy, Combination | Prevention | Treatment outcome | Cardiovascular diseases | Drug therapy | Analysis | Stroke | Monoclonal antibodies | Cardiovascular disease | Patients | Drug dosages | Low density lipoprotein | Statins | Clinical outcomes | Cholesterol | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
by Wiviott, Stephen D and Raz, Itamar and Bonaca, Marc P and Mosenzon, Ofri and Kato, Eri T and Cahn, Avivit and Silverman, Michael G and Zelniker, Thomas A and Kuder, Julia F and Murphy, Sabina A and Bhatt, Deepak L and Leiter, Lawrence A and McGuire, Darren K and Wilding, John P.H and Ruff, Christian T and Gause-Nilsson, Ingrid A.M and Fredriksson, Martin and Johansson, Peter A and Langkilde, Anna-Maria and Sabatine, Marc S and DECLARE-TIMI 58 Investigators and DECLARE–TIMI 58 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 4, pp. 347 - 357
In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher... 
2013 ACCF/AHA GUIDELINE | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | MANAGEMENT | HEART-FAILURE OUTCOMES | DISEASE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | KIDNEY | EMPAGLIFLOZIN | SOCIETY | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
by Ruff, Christian T, Dr and Giugliano, Robert P, MD and Braunwald, Eugene, Prof and Morrow, David A, MD and Murphy, Sabina A, MPH and Kuder, Julia F, MA and Deenadayalu, Naveen, MPH and Jarolim, Petr, MD and Betcher, Joshua, PhD and Shi, Minggao, PhD and Brown, Karen, PhD and Patel, Indravadan, MD and Mercuri, Michele, MD and Antman, Elliott M, Prof
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9984, pp. 2288 - 2295
Summary Background New oral anticoagulants for stroke prevention in atrial fibrillation were developed to be given in fixed doses without the need for the... 
Internal Medicine | STROKE | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | METAANALYSIS | THERAPY | WARFARIN | GUIDELINES | INTENSITY | ATRIAL-FIBRILLATION | ANTICOAGULATION | Stroke - prevention & control | Pyridines - administration & dosage | Double-Blind Method | Atrial Fibrillation - drug therapy | Humans | Atrial Fibrillation - complications | Pyridines - pharmacokinetics | Factor Xa Inhibitors - pharmacokinetics | Thiazoles - administration & dosage | Treatment Outcome | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Factor Xa Inhibitors - administration & dosage | Pyridines - adverse effects | Factor Xa Inhibitors - adverse effects | Hemorrhage - chemically induced | Clinical trials | Warfarin | Analysis | Atrial fibrillation | Anticoagulants | Cardiac arrhythmia | Stroke | Drug dosages | Medical treatment | Mortality | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial
by Bohula, Erin A and Giugliano, Robert P and Ruff, Christian T and Kuder, Julia F and Murphy, Sabina A and Antman, Elliott M and Braunwald, Eugene
Circulation, ISSN 0009-7322, 07/2016, Volume 134, Issue 1, pp. 24 - 36
BACKGROUND:Edoxaban, an oral factor Xa inhibitor with 50% renal clearance, was noninferior to well-managed warfarin for stroke or systemic embolism (S/SE)... 
anticoagulants | kidney | atrial fibrillation | thromboembolism | warfarin | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | EFFICACY | SAFETY | XA INHIBITOR EDOXABAN | RISK | ANTICOAGULATION | STROKE | PERIPHERAL VASCULAR DISEASE | NONVALVULAR ATRIAL-FIBRILLATION | SYSTEMIC EMBOLISM | Follow-Up Studies | Humans | Middle Aged | Pyridines - pharmacokinetics | Warfarin - adverse effects | Male | Metabolic Clearance Rate | Risk | Thiazoles - therapeutic use | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Kidney Function Tests | Thrombophilia - etiology | Warfarin - therapeutic use | Creatinine - metabolism | Kidney - metabolism | Pyridines - adverse effects | Aged, 80 and over | Female | Thrombophilia - drug therapy | Pyridines - therapeutic use | Double-Blind Method | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Factor Xa Inhibitors - pharmacokinetics | Anticoagulants - adverse effects | Warfarin - pharmacokinetics | Factor Xa Inhibitors - therapeutic use | Factor Xa Inhibitors - adverse effects | Aged | Anticoagulants - pharmacokinetics | Hemorrhage - chemically induced | Prevention | Clinical trials | Care and treatment | Usage | Hemorrhage | Atrial fibrillation | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial
by Storey, Robert F., MD, DM and Angiolillo, Dominick J., MD and Bonaca, Marc P., MD, MPH and Thomas, Mark R., MD and Judge, Heather M., PhD and Rollini, Fabiana, MD and Franchi, Francesco, MD and Ahsan, Arif J., MD and Bhatt, Deepak L., MD, MPH and Kuder, Julia F., MA and Steg, Philippe Gabriel, MD and Cohen, Marc, MD and Muthusamy, Rangasamy, MD and Braunwald, Eugene, MD and Sabatine, Marc S., MD, MPH
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2016, Volume 67, Issue 10, pp. 1145 - 1154
Abstract Background The PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a... 
Cardiovascular | Internal Medicine | coronary artery disease | P2Y12 receptor | aspirin | Key Words aspirin | receptor | P2Y | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | ADENOSINE-DIPHOSPHATE | CARDIOVASCULAR EVENTS | RECEPTOR ANTAGONIST | PERCUTANEOUS CORONARY INTERVENTION | CLOPIDOGREL | P2Y receptor | ST-SEGMENT ELEVATION | LIGHT TRANSMISSION AGGREGOMETRY | CLINICAL-OUTCOMES | ARTERY-DISEASE | Myocardial Infarction - blood | Adenosine - pharmacokinetics | Purinergic P2Y Receptor Antagonists - administration & dosage | Follow-Up Studies | Humans | Purinergic P2Y Receptor Antagonists - pharmacokinetics | Treatment Outcome | Adenosine - administration & dosage | Dose-Response Relationship, Drug | Myocardial Infarction - drug therapy | Time Factors | Adenosine - analogs & derivatives | Platelet Aggregation - drug effects | Blood Platelets - drug effects | Prevention | Medical colleges | Aspirin | Hospitals | Cardiac patients | Research institutes | Cardiology | Heart diseases | Confidence intervals | Adenosine | Phosphorylation | Heart attacks | Blood platelets | Coronary vessels | Cardiovascular disease | Acute coronary syndromes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial
by O’Donoghue, Michelle L and Glaser, Ruchira and Cavender, Matthew A and Aylward, Philip E and Bonaca, Marc P and Budaj, Andrzej and Davies, Richard Y and Dellborg, Mikael and Fox, Keith A. A and Gutierrez, Jorge Antonio T and Hamm, Christian and Kiss, Robert G and Kovar, František and Kuder, Julia F and Im, Kyung Ah and Lepore, John J and Lopez-Sendon, Jose L and Ophuis, Ton Oude and Parkhomenko, Alexandr and Shannon, Jennifer B and Spinar, Jindrich and Tanguay, Jean-Francois and Ruda, Mikhail and Steg, P. Gabriel and Theroux, Pierre and Wiviott, Stephen D and Laws, Ian and Sabatine, Marc S and Morrow, David A and LATITUDE-TIMI 60 Investigators and for the LATITUDE-TIMI 60 Investigators and Sahlgrenska akademin and Institute of Medicine and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy and Institutionen för medicin
JAMA, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1591 - 1599
IMPORTANCE: p38 Mitogen-activated protein kinase (MAPK)–stimulated inflammation is implicated in atherogenesis, plaque destabilization, and maladaptive... 
Recurrence | Myocardial Infarction - mortality | Humans | Middle Aged | Male | Secondary Prevention | Cyclopropanes - adverse effects | Protein Kinase Inhibitors - adverse effects | Cyclopropanes - therapeutic use | Pyridines - adverse effects | Treatment Failure | Female | C-Reactive Protein - analysis | Myocardial Infarction - enzymology | Pyridines - therapeutic use | Double-Blind Method | Drug Administration Schedule | Myocardial Ischemia - prevention & control | Hospitalization | Myocardial Revascularization | Algorithms | Myocardial Infarction - drug therapy | Protein Kinase Inhibitors - therapeutic use | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | Aged | Myocardial Ischemia - surgery | Clinical trials | Care and treatment | Usage | Dosage and administration | Extracellular signal-regulated kinases | Heart attack | Patient safety | Inhibitor drugs | Heart attacks | Clinical outcomes | Index Medicus | Abridged Index Medicus | Pyridines/adverse effects/therapeutic use | Cyclopropanes/adverse effects/therapeutic use | C-Reactive Protein/analysis | Klinisk medicin | Clinical Medicine | p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors | Myocardial Ischemia/prevention & control/surgery | Protein Kinase Inhibitors/adverse effects/therapeutic use | Myocardial Infarction/drug therapy/enzymology/mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights